Trials of prostate-cancer screening are not worthwhile
Author:
- 1 March 2009
- journal article
- Published by Elsevier in The Lancet Oncology
- Vol. 10 (3) , 294-298
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Overdiagnosis and overtreatment of early detected prostate cancerWorld Journal of Urology, 2007
- Extent of Prostate-Specific Antigen Contamination in the Spanish Section of the European Randomized Study of Screening for Prostate Cancer (ERSPC)European Urology, 2006
- Why Most Published Research Findings Are FalsePLOS Medicine, 2005
- Determining overdiagnosis by screening with DRE/TRUS or PSA (Florence pilot studies, 1991–1994)European Journal of Cancer, 2005
- Clinical Consequences of Screening for Prostate Cancer: 15 Years Follow-up of a Randomised Controlled Trial in SwedenEuropean Urology, 2004
- Prostate cancer mortality reduction by screening: Power and time frame with complete enrollment in the European randomised screening for prostate cancer (ERSPC) trialInternational Journal of Cancer, 2001
- Large‐scale randomized prostate cancer screening trials: Program performances in the European randomized screening for prostate cancer trial and the prostate, lung, colorectal and ovary cancer trialInternational Journal of Cancer, 2001
- No randomised trial of prostatecancer screening in NorwayThe Lancet Oncology, 2001
- Is the Pope an alien?Nature, 1996
- Statistical Issues in the Planning of Prevention StudiesCancer Investigation, 1988